# A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

> **NCT07014826** · PHASE3 · RECRUITING · sponsor: **Chengdu Suncadia Medicine Co., Ltd.** · enrollment: 378 (estimated)

## Conditions studied

- Primary IgA Nephropathy

## Interventions

- **DRUG:** HRS-5965
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07014826
- **Lead sponsor:** Chengdu Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2027-10
- **Final completion:** 2028-12
- **Target enrollment:** 378 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07014826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07014826, "A Trial of HRS-5965 Capsule in Primary IgA Nephropathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07014826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*